Hydrogel-Mediated Cancer Immunotherapy: Material Design, Immune Regulation and Translation
Pharmaceutics · 20.11.2026 · 18 (11) · 1498
DOI: 10.3390/pharmaceutics18111498 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 20.11.2026. Verfasst von Lu Ren und 3 weiteren Autor:innen. Die Arbeit nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Durable responses to cancer immunotherapy remain difficult to achieve in many solid tumors, where rapid clearance and inadequate intratumoral exposure combine with immunosuppression and systemic toxicity to limit treatment benefit. Local hydrogel delivery offers a way to concentrate immunomodulatory signals at the lesion, although its performance varies with the formulation, payload, and tumor setting. Drawing on melanoma, breast cancer, and other solid-tumor models, this review relates hydrogel design to payload-mediated immune regulation, combination therapy, and preclinical translation. Injectable and in situ-forming systems have prolonged local exposure to immunogenic cell death inducers, adjuvants, cytokines, and checkpoint inhibitors, while also supporting adoptive cell delivery. Some multicomponent formulations release their payloads at different times, but the contribution of this sequence to efficacy remains unresolved. Selected syngeneic studies report improved local control and reduced recurrence or metastasis, with abscopal responses or rechallenge protection in some cases. Across these studies, retention and release kinetics, considered together with the payload, appear more informative than material class alone. Because most reports evaluate individual immune endpoints, coordinated regulation across the cancer–immunity cycle has yet to be demonstrated. Durable clinical benefit also remains unproven. We examine these findings in relation to matrix properties, release behavior, tumor heterogeneity, and model selection, separating demonstrated effects from design potential. Clinical development will require formulations suited to specific indications, standardized immune and safety assessment, and scalable manufacture, supported by clinical tests of defined mechanisms beyond general claims about the platform.
Zitieren
APA
Ren, L., Li, X., Yang, J., & Qiao, H. (2026). Hydrogel-Mediated Cancer Immunotherapy: Material Design, Immune Regulation and Translation. Pharmaceutics, 18(11), 1498. https://doi.org/10.3390/pharmaceutics18111498
Vancouver
Ren L, Li X, Yang J, Qiao H. Hydrogel-Mediated Cancer Immunotherapy: Material Design, Immune Regulation and Translation. Pharmaceutics. 2026;18(11):1498. doi:10.3390/pharmaceutics18111498
BibTeX
@article{Ren2026,
author = {Ren, Lu and Li, Xin and Yang, Jingdu and Qiao, Haifa},
title = {Hydrogel-Mediated Cancer Immunotherapy: Material Design, Immune Regulation and Translation},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1498},
doi = {10.3390/pharmaceutics18111498}
}
EUVIMED